Download Pioneer Skin For Virtual Dj 8

[Alethia Tiell]

Ourultimate objective is to build capability in non-animal alternatives, worldwide. To share our message across the globe, we have published our research in over 1,000 peer-reviewed research papers in many scientific journals, and presented our work in innumerable international conferences. We continue to advocate strongly for the regulatory acceptance of non-animal methods to help make animal-testing obsolete.

P&G scientists invented one of the first non-animal alternative methods for skin allergy testing, which was recently approved by key authorities. This method marks a milestone in eliminating the need for animal testing.

Understanding Skin Sensitization

By learning about how the two phases of skin sensitization occurs, P&G is creating new ways to test our products safely and effectively through non-animal methods.

Another scientific area P&G experts are leading is Read-Across, a method to predict the safety profile of new-to-the-world ingredient innovations based on chemical and biological properties of known ingredients.

Pioneering the Elimination of Eye Testing

P&G helped pioneer eye testing without the use of animals by using cell culture tests and reconstructed human tissue. A cornerstone of our work in this area has been to lead key international programs and industry activities, all with the aim to optimize these non-animal tests, extend their application to all types of ingredients, and to secure regulatory acceptance. These efforts contribute to the greater good, enabling P&G and all of industry to develop cruelty-free, safe products.

Oral cavity, tonsils, base of tongue, hypopharynx, larynx: We specialize in both HPV negative and HPV positive cancers. For both types of cancer, our goal is to cure cancer with the lowest possible long term side effects. The most commonly used standard agent in combination with radiation therapy is cisplatin. When we give cisplatin, we favor a weekly schedule that breaks up the dose over a large dose every three weeks. This allows us to adjust nimbly based on tolerance and side effects. When cisplatin is not possible, we use laboratory testing to ensure low risk of allergic reactions with cetuximab.

When these cancers have spread and/or are no long curable, we use anti-cancer therapies to shrink them, with the goals of extending duration of life and preserving quality of life. We helped pioneer the use of immunotherapy for squamous head and neck cancer and continue to favor its use for appropriately selected patients. When chemotherapy is required, we choose agents and schedules that minimize side effects and we provide aggressive supportive care to improve overall patient well-being.

Anaplastic thyroid cancer: We have a multidisciplinary treatment team that is dedicated to the treatment of this deadly cancer. We have adopted practices to conduct molecular testing for all new diagnoses, which allows us tailor our treatment selection. We consider the use of targeted therapy for all patients who have a mutation in the BRAF. We are opening new clinical trials that will help patients with anaplastic disease and have a vested interest to become national experts in the treatment of this cancer.

We routinely conduct advanced molecular testing to seek a targeted therapy option based on the molecular genetics of the individual tumor, for when treatment is needed. When no actionable target is found, and treatment is required, we use targeted therapies to block the blood supply to the tumor. While there are always exceptions for unusual cases, we almost never use chemotherapy for differentiated thyroid cancer.

Medullary thyroid cancer: We helped pioneer the use of RET targeted therapeutics for these cancers and continue to favor their use when RET mutation is present. When absent, we employ advanced molecular diagnostics to seek other targeted therapy options. When not present, we work closely with the neuro-endocrine group to consider optimal therapeutics.

Sinonasal (NUT carcinoma, squamous cell carcinoma, sinonasal undifferentiated carcinoma (SNUC), sinonasal adenocarcinoma (SNAC): we have a growing expertise in these rare cancers of the sinus cavities and nasal track. We are developing studies to give anti-cancer therapies prior to surgery to maximize the chance of cure with surgery and/or radiation therapy.

Salivary tumors (adenoid cystic carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma): Curative therapy of these malignancies is mostly surgical. When medicines are required, it is typically for cancers that have spread outside of the head and neck and/or are no longer curable. In these cases, we seek to maximize both quality of life and duration of life. Our first question is always whether treatment is truly required, or whether observation might be a better option. When treatment is required, we used advanced immunohistochemical testing and molecular testing to identify targeted, non-chemotherapeutic options.

Squamous skin cancer: We primarily utilize immunotherapy agents to treat squamous skin cancers, when systemic therapy is required either prior to surgery or in patients with metastatic disease. We offer clinical trials for patients with these cancer in hopes of developing improved anti-cancer treatments

As Extended Reality (XR) continues to develop, the role of haptics becomes ever more crucial. Delivering a rich sensory experience is a key aspect of VR/AR applications, and touch interaction, commonly known as haptics, plays a vital role in shaping these experiences. SenseGlove, a pioneer in the haptics realm, recently released an insightful eBook that delves into the intricacies of haptics. It's a must-read for anyone seeking to understand the expanding world of haptics in VR and XR.

The eBook, a compilation of expert interviews from the Haptics Club Podcast, offers a comprehensive understanding of haptics applications across multiple industries. Let's take a look at the top insights:

The eBook explores the concept of chemical haptics, where chemicals applied to the skin stimulate various skin receptors to create different sensations. This fascinating research opens up new possibilities for creating immersive and long-lasting haptic experiences.

Daniel Shor takes an in-depth look at how haptics can transform the sexual wellness industry. From rhythms and patterns to the sense of intimacy, emotion, and connection, he explains the unique benefits of integrating haptics in this realm.

The eBook concludes with a look at how haptics can enhance VR gaming. The ease of integration and the elevated user experience it offers make haptics a game-changer in the world of virtual reality gaming.

The SenseGlove eBook shines a spotlight on the importance of making haptics accessible and desirable to the consumer. It underscores the critical role of continuous innovation and ease of use in shaping the future of the haptics industry. The underlying message is clear: for haptics to progress, it must find its way into the hands of the consumer in a straightforward, appealing manner.

By offering detailed insights from industry experts, the SenseGlove eBook serves as an excellent guide for anyone interested in the fast-evolving world of haptics in VR and XR. Whether you're an XR enthusiast, a budding developer, or a seasoned professional, this eBook provides a rich understanding of the current haptics landscape and its potential for the future. A new age of touch interaction is on the horizon, and as SenseGlove is demonstrating, it's a future where haptics take center stage.

3a8082e126